SLC5A2 and kidney disorder: Furthermore, data from EMPA-KIDNEY indicates that the benefit of SGLT-2 inhibition in terms of progression of kidney disease is not attenuated in people with an eGFR < 20 mL/min/1.73m2 (Fig. 4).